10 results match your criteria Community Oncology[Journal]

  • Page 1 of 1

Considerations in the initial management of follicular lymphoma.

Community Oncol 2012 Nov;9(11):S53-S60

Winship Cancer Institute, Emory University, Atlanta, GA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cmonc.2012.09.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3610920PMC
November 2012
11 Reads

Management of relapsed chronic lymphocytic leukemia: applying guidelines to practice.

Community Oncol 2012 Dec;9(12):S85-S92

Winship Cancer Institute, Emory University, Atlanta, GA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cmonc.2012.09.019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541037PMC
December 2012
12 Reads

Why do cancer patients smoke and what can providers do about it?

Community Oncol 2012 Nov 17;9(11):344-352. Epub 2012 Nov 17.

Ann Arbor VA Center for Clinical Management Research, Michigan ; Departments of Otolaryngology, Psychiatry, and School of Nursing, University of Michigan, Ann Arbor.

Despite the widespread dissemination of information about the health risks associated with smoking, many cancer patients continue to smoke, which results in a decreased quality of life, an increased probability of cancer recurrence, and a decreased survival time. Efficacious interventions are available to assist cancer patients to quit smoking, yet smoking cessation interventions are often not implemented. This review describes how clinicians, administrators, insurers, and purchasers can encourage a culture of health care in which tobacco cessation interventions are implemented consistent with evidenced-based standards of care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cmonc.2012.10.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3500959PMC
November 2012
13 Reads

ASCO beyond McCormick: perseverance, collaboration, mentorship.

Authors:
Joseph W Kim

Community Oncol 2012 Aug;9(8):265

Laboratory of Tumor Immunology and Biology and Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cmonc.2012.07.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460519PMC
August 2012
11 Reads

Cancer patients' use of pharmaceutical patient assistance programs in the outpatient pharmacy at a large tertiary cancer center.

Community Oncol 2011 Jun 10;8(6):279-286. Epub 2012 Feb 10.

Division of Health Promotion & Behavioral Sciences, University of Texas School of Public Health, 7000 Fannin, Suite 2510F, Houston, Texas, 77030 (USA).

PURPOSE: To report on the use of pharmaceutical patient assistance programs (PAPs) in the outpatient pharmacy at the largest tertiary cancer center in the United States. METHODS: We conducted a retrospective (July 1, 2006-Dec 31,2007) cross-sectional analysis of outpatient pharmacy, medical, and cancer registry records at the cancer center. The cancer center identified 104 medications available through PAPs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1548-5315(12)70023-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413301PMC
June 2011
16 Reads

Update on paraneoplastic neurologic disorders.

Community Oncol 2010 May;7(5):219-224

Dr. Dalmau is Professor of Neurology, and Dr. Rosenfeld is Professor of Neurology and Chief of the Division of Neuro-oncology, at the University of Pennsylvania, Philadelphia.

Once considered rare, paraneoplastic neurologic disorders (PNDs) are an extensive group of neurologic disorders that occur either exclusively or at increased frequency in patients with cancer. PNDs have been increasingly recognized due in large part to the identification of antineuronal antibodies in the serum and cerebrospinal fluid of patients. Although almost any neoplasm can cause PND, the tumors most commonly involved are small-cell lung cancer, cancers of the breast and ovary, thymoma, neuroblastoma, plasma cell tumors, and ovarian teratoma. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092704PMC
May 2010
10 Reads

Exercise, sleep quality, and mediators of sleep in breast and prostate cancer patients receiving radiation therapy.

Community Oncol 2010 Oct;7(10):463-471

Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY.

Cancer patients often report impaired sleep quality. Impaired sleep quality may be due to increased levels of sleep-mediating cytokines resulting from cancer treatment. Exercise may have a positive influence on sleep-mediating cytokines, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and soluble tumor necrosis factor-alpha receptor (sTNF-R), which may improve sleep quality. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3026283PMC
October 2010
16 Reads

Sildenafil- and tadalafil-associated optic neuropathy: implications for men after prostate cancer treatment.

Community Oncol 2009 Feb;6(2):78-80

Division of Geriatric Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2800378PMC
February 2009
25 Reads

AIs: implications for fractures in perimenopausal women with breast cancer.

Community Oncol 2008 Nov;5(11):625-626

Bone Health and Osteoporosis Program and Division of Geriatric Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3028269PMC
November 2008
14 Reads

Gadolinium-associated nephrogenic systemic fibrosis.

Community Oncol 2008 ;5(6):325-326

The Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL.

The authors explain why physicians should refrain from ordering MRIs for patients with renal dysfunction unless the test is essential to provide diagnostic information. A possibly class-wide toxicity from the contrast agent gadolinium has been reported. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2777717PMC
January 2008
24 Reads
  • Page 1 of 1